Statistics from Altmetric.com
S P Liimatainen, J A Raitanen, A M Ylinen, et al. J Nerol Neurosurg Psychiatry, 2008; 79:808–12. The benefit of active drug trials is dependent on aetiology in refractory focal epilepsy. There is an error in the results section in the second paragraph: “The chances of achieving the remission were significantly higher in the patients with cryptogenic aetiology compared with symptomatic aetiologies (age-adjusted OR 3.74, 95% CI 1.54 to 9.07, p = 0.04).” The correct p value should be 0.004, not 0.04.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.